% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Krilaviciute:132823,
author = {A. Krilaviciute$^*$ and C. Stock$^*$ and M. Leja and H.
Brenner$^*$},
title = {{P}otential of non-invasive breath tests for preselecting
individuals for invasive gastric cancer screening
endoscopy.},
journal = {Journal of breath research},
volume = {12},
number = {3},
issn = {1752-7163},
address = {Bristol},
publisher = {IOP},
reportid = {DKFZ-2018-00467},
pages = {036009 -},
year = {2018},
abstract = {Regular screening for gastric cancer (GC) is based on
invasive upper gastrointestinal endoscopy and is limited to
few high-incidence countries. As GC is a major cause of
cancer death worldwide, a non-invasive, simple screening
test is of value. We assessed the prevalence of preclinical
GC and the corresponding numbers needed to screen (NNS) to
detect GC cases both without and with preselection using
breath tests from the literature in various
populations.Using age- and sex-specific GC incidence data
and rates of transition from preclinical to clinical GC, we
estimated the prevalences of preclinical GC worldwide in
populations aged 50-74 years, and we evaluated the accuracy
of breath testing for GC detection based on published
studies. We then derived the expected positive predictive
values for breath testing in populations with different
preclinical GC prevalences.Four studies reporting the
sensitivity and specificity of breath tests were identified,
and summary estimates of $83\%$ sensitivity and $91\%$
specificity were derived by meta-analysis. The estimates of
the overall prevalence of preclinical GC were $<0.5\%$ in
men and $<0.2\%$ in women aged 50-74 years across different
regions of the world. The positive predictive values, the
prevalence among breath test positive people, were
approximately nine-fold higher in all populations, resulting
in an approximately nine-fold lower NNS to detect one GC
case when breath tests were used for preselection for
screening.Given the low prevalence of preclinical GC,
non-invasive breath tests show promise for making screening
more efficient. Further validation of breath tests and
evidence on the rates of transition from preclinical to
clinical GC are needed to validate the breath test
approach.},
cin = {C070 / G110 / L101},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331 /
I:(DE-He78)L101-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29528036},
doi = {10.1088/1752-7163/aab5be},
url = {https://inrepo02.dkfz.de/record/132823},
}